Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2014

Filing Date
Filed March 2, 2015
Period End
December 31, 2014
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 2, 2015. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. ("Exelixis") is a biopharmaceutical company developing small molecule cancer therapies.

Its focus is cabozantinib, which is approved in the U.S. and EU for progressive, metastatic medullary thyroid cancer under the brand name COMETRIQ. COMETRIQ generated net product revenues of $25.1 milliona in 2014, and the company reported $40.1 million in net revenues from COMETRIQ since its January 2013 launch. Cabozantinib's phase 3 trials in metastatic castration-resistant prostate cancer (COMET-1 and COMET-2) did not meet their primary endpoints, and development in that indication has been terminated.

The remaining key pipeline programs are two ongoing phase 3 trials, METEOR in metastatic renal cell carcinoma (top-line data expected in Q2 2015) and CELESTIAL in advanced hepatocellular carcinoma (results expected in 2017). Partner Genentech has an NDA for cobimetinib with priority review and a PDUFA date of August 11, 2015. Financially, the company reported a net loss of $268.5 millionb for 2014, up from $244.8 million in 2013, and an accumulated deficit of $1.8 billion.

Total cash and investments were $242.8 millionc at year-end, of which $144.3 million was available for operations. Stockholders' deficit was $(114.8) million. Total debt was $361.7 million, including $287.5 million of 4.25% convertible notes due 2019 and $104.0 million of Deerfield Notes due July 1, 2015 unless extended.

The company states it expects to maintain operations through at least December 31, 2015, and that its ability to sustain operations beyond that is highly dependent on COMETRIQ sales and the cobimetinib collaboration. A 2014 restructuring reduced the workforce to approximately 80 full-time employees. For investors, the central issues are the company's need for additional capital, its dependence on the success of cabozantinib in its remaining phase 3 trials and on Genentech's cobimetinib launch, and the near-term Deerfield Notes maturity, which the company plans to extend to July 2018 by exercising an option that must be exercised before March 31, 2015.

Key Highlights

  1. Net loss of $268.5 million for 2014 versus $244.8 million in 2013; accumulated deficit of $1.8 billion.
  2. Net product revenues of $25.1 million in 2014 from COMETRIQ, compared with $15.0 million in 2013; COMETRIQ net revenues since launch total $40.1 million.
  3. Cash and investments of $242.8 million at December 31, 2014, with $144.3 million available for operations; the company expects to fund operations through at least December 31, 2015.
  4. Total debt of $361.7 million, including $287.5 million of 2019 convertible notes and $104.0 million of Deerfield Notes maturing July 1, 2015 unless extended.
  5. Cabozantinib phase 3 trials in mCRPC (COMET-1 and COMET-2) failed primary endpoints; clinical development in mCRPC has been terminated.
  6. Pivotal METEOR (mRCC) top-line data expected Q2 2015; CELESTIAL (HCC) top-line results expected 2017.
  7. Genentech's NDA for cobimetinib with vemurafenib has priority review, with a PDUFA date of August 11, 2015; Exelixis shares U.S. profits and costs.

Financial Statements

FY2014 against FY2013

Line itemFY2014FY2013Change
Revenue$25.11M$31.34M−19.9%
Cost of Revenue$2.04M$1.12M+82.7%
Gross Profit$23.07M$30.22M−23.7%
R&D Expenses$189.10M$178.76M+5.8%
SG&A Expenses$50.83M$50.96M−0.3%
Operating Expenses$249.57M$232.07M+7.5%
Operating Income-$224.46M-$200.73M−11.8%
Interest Expense$41.36M$38.78M+6.7%
Net Income-$261.30M-$238.19M−9.7%
EPS (Basic)$-1.34$-1.29−3.9%
Shares Outstanding (Basic)194.30M184.06M+5.6%

Frequently Asked Questions

  1. Does Exelixis have enough cash to fund its operations?

    The company states that its current cash and cash equivalents, short-term investments available for operations, and product revenues will enable it to maintain operations through at least December 31, 2015. Beyond the next twelve months, its ability to sustain operations is highly dependent on COMETRIQ sales and the cobimetinib collaboration. It may need to raise additional capital through equity, debt, or partnering, and it states that such transactions are unclear in timing and terms.

  2. What is the status of the Deerfield Notes?

    The Deerfield Notes have $104.0 million principal outstanding and mature on July 1, 2015. The company has an option to extend the maturity to July 1, 2018 for $100.0 million of principal, which must be exercised by notice before March 31, 2015. If extended, interest is 7.5% payable in cash plus 7.5% payable in kind, for a total of 15% per annum. The company states it currently expects to exercise the option.

  3. Why was cabozantinib's prostate cancer program stopped?

    COMET-1 did not meet its primary endpoint of a statistically significant increase in overall survival compared with prednisone, announced September 1, 2014. COMET-2 did not meet its primary endpoint of alleviating bone pain, announced December 1, 2014. Based on these results, the company terminated clinical development of cabozantinib in mCRPC and initiated a restructuring that reduced its workforce.

  4. What are the key near-term catalysts for investors?

    The filing identifies top-line METEOR safety and efficacy data in mRCC expected in the second quarter of 2015, the FDA action date of August 11, 2015 for Genentech's cobimetinib NDA, and the Deerfield Notes extension decision due by March 31, 2015. CELESTIAL top-line results in HCC are expected in 2017.

  5. How is the cobimetinib collaboration structured?

    Genentech leads development and commercialization. Exelixis is entitled to an initial equal share of U.S. profits and losses, with its share decreasing as sales increase: 50% of profits from the first $200 million of U.S. sales, falling to 30% above $400 million. It shares equally in U.S. marketing costs and may provide up to 25% of the U.S. sales force. It is also entitled to low double-digit royalties on ex-U.S. net sales.